Reply
- PMID: 33161642
- DOI: 10.1002/acr.24378
Reply
Comment on
-
Ustekinumab for the Treatment of Giant Cell Arteritis.Arthritis Care Res (Hoboken). 2021 Jun;73(6):893-897. doi: 10.1002/acr.24200. Arthritis Care Res (Hoboken). 2021. PMID: 32248659 Clinical Trial.
-
Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al.Arthritis Care Res (Hoboken). 2021 Jul;73(7):1058-1059. doi: 10.1002/acr.24376. Epub 2021 Jun 4. Arthritis Care Res (Hoboken). 2021. PMID: 32702165 No abstract available.
References
-
- Samson M, Ghesquiere T, Berthier S, Bonnotte B. Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis. Ann Rheum Dis 2018;77:e6.
-
- Stelara [package insert]. Horsham PA: Janssen Pharmaceutical Companies; 2016.
-
- Conway R, O’Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum 2018;48:523-8.
-
- Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014;93:194-201.
-
- Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol 2019;71:1329-38.